Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 21 November 2017

LIDDS: Patent granted in India for prostate cancer treatment


Published: 09:30 CET 21-11-2017 /GlobeNewswire /Source: LIDDS AB / : LIDDS /ISIN: SE0001958612

LIDDS: Patent granted in India for prostate cancer treatment

LIDDS has received approval from the Indian patent office for its patent on "Method for treatment of prostate cancer and other prostate diseases" with the NanoZolid® drug delivery technology formulation.


The approved patent protects means of administering active substances to the prostate gland for high local efficacy while avoiding systemic side effects. The patent provides protection for the Liproca® Depot product as well as other NanoZolid products for prostate diseases.


The approval concerns the WO2006103112 patent application, which corresponds to the Indian patent no. 287 112.


The grant of the patent in India concludes the evaluation phase since all countries now have approved this patent application and all major markets are protected.


For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com                     


LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 21 November 2017 at 09.30 CET.


About Lidds

LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company's most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS. For more information, go to www.liddspharma.com.  

The News in PDF

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: LIDDS AB, Kullagatan 8, Helsingborg SE-252 20, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.